ABOUT JGMV

The Journal of General and Molecular Virology (JGMV) (ISSN 2141-6648) is published per article (one volume per year) by Academic Journals.

Journal of General and Molecular Virology (JGMV), is a peer reviewed journal. The journal is published per article and covers all areas of the subject such as: Isolation of chikungunya virus from non-human primates, Functional analysis of Lassa virus glycoprotein from a newly identified Lassa virus strain for possible use as vaccine using computational methods, as well as Molecular approaches towards analyzing the viruses infecting maize.

Submission of Manuscript

Please read the Instructions for Authors before submitting your manuscript. The manuscript files should be given the last name of the first author.

Click here to Submit manuscripts online

If you have any difficulty using the online submission system, kindly submit via this email jgmv@academicjournals.org.

With questions or concerns, please contact the Editorial Office at jgmv@academicjournals.org.
Editor-In-Chief

Dr. Jiguo Chen
Alaska State Public Health Virology Laboratory
University of Alaska Fairbanks
Fairbanks, AK
USA.

Editor

Dr. Hossam M Ashour
Department of Microbiology and Immunology
Faculty of Pharmacy
Cairo University
Egypt.
Instructions for Author

Electronic submission of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The cover letter should include the corresponding author’s full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author’s surname, as an attachment.

Article Types
Three types of manuscripts may be submitted:

Regular articles: These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

Short Communications: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

Reviews: Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

Review Process
All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers’ comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the AJFS to publish manuscripts within weeks after submission.

Regular articles
All portions of the manuscript must be typed double-spaced and all pages numbered starting from the title page.

The Title should be a brief phrase describing the contents of the paper. The Title Page should include the authors’ full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited. Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard Abbreviations should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

The Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

Materials and methods should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer’s name and address. Subheadings should be used. Methods in general use need not be described in detail.
Results should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors' experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

The Discussion should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

The Acknowledgments of people, grants, funds, etc should be brief.

Tables should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

Figure legends should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

References: In the text, a reference identified by means of an author’s name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author’s name should be mentioned, followed by ‘et al’. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like ‘a’ and ‘b’ after the date to distinguish the works.

Examples:

Abayomi (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 1992), (Chege, 1998; 1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001)

References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:


Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage.
Fees and Charges: Authors are required to pay a $550 handling fee. Publication of an article in the Journal of General and Molecular Virology is not contingent upon the author’s ability to pay the charges. Neither is acceptance to pay the handling fee a guarantee that the paper will be accepted for publication. Authors may still request (in advance) that the editorial office waive some of the handling fee under special circumstances.

All rights Reserved. In accessing this journal, you agree that you will access the contents for your own personal use but not for any commercial use. Any use and or copies of this Journal in whole or in part must include the customary bibliographic citation, including author attribution, date and article title.

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

Disclaimer of Warranties

In no event shall Academic Journals be liable for any special, incidental, indirect, or consequential damages of any kind arising out of or in connection with the use of the articles or other material derived from the JGMV, whether or not advised of the possibility of damage, and on any theory of liability. This publication is provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication. While every effort is made by Academic Journals to see that no inaccurate or misleading data, opinion or statements appear in this publication, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Academic Journals makes no warranty of any kind, either express or implied, regarding the quality, accuracy, availability, or validity of the data or information in this publication or of any other publication to which it may be linked.
Subgenogroup B5 maintains its supremacy over other human Enterovirus71 strains that circulated in Malaysia from 2010 to 2012
Mohd Apandi Yusof, Hariyati Md Ali, Hamadah Mohammad Shariff, Noor Khairunnisa Ramli, Zarina Mohd Zawawi, Syarifah Nur Aisyatun, Jasinta Anak Dennis and Zainah Saat
Full Length Research Paper

Subgenogroup B5 maintains its supremacy over other human Enterovirus71 strains that circulated in Malaysia from 2010 to 2012

Mohd Apandi Yusof*, Hariyati Md Ali, Hamadah Mohammad Shariff, Noor Khairunnisa Ramli, Zarina Mohd Zawawi, Syarifah Nur Aisyatun, Jasinta Anak Dennis and Zainah Saat

Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia.

Received 30 September, 2013; Accepted 5 May, 2014

Human enterovirus71 (HEV71) is responsible for hand, foot and mouth diseases (HFMD). Several outbreaks of HFMD were associated with severe neurological disease and deaths. In Malaysia, outbreaks normally occur periodically every two to three years but HEV71 were isolated throughout the year from HFMD cases. From 2010 to 2012, HEV71 strains were isolated from 37 children presented with typical HFMD. All isolates were sequenced and BLAST searched. A phylogenetic tree constructed based on the complete VP1 gene showed that all isolates belonged to subgenogroup B5. This subgenogroup has been found dominant since 2003.

Key words: Human enterovirus71, molecular epidemiology, gene sequences, circulating subgenogroup.

INTRODUCTION

Human enterovirus71 (HEV71) is classified under the human enterovirus A species. It is a positive-sense RNA virus from enterovirus genus in the family picornaviridae. Together with Coxsackie A16 and Coxsackie A6, they cause major outbreaks of hand foot and mouth disease (HFMD) in children. During outbreaks in Sarawak, Malaysia in 1997 (Chan et al., 2000) and Taiwan in 1998 (Wang et al., 2002), HEV71 infections not only presented with typical HFMD but were also associated with neurological disorders such as encephalitis, aseptic meningitis and meningoencephalitis (McMinn et al., 2001; Kehle et al., 2003), and paralysis (Melnick, 1984) due to its affinity to anterior horn cell (Chumakov et al., 1979).

HFMD outbreaks associated with HEV71 had been reported globally. In the Asia Pacific region, large outbreaks have been recorded in Sarawak and Peninsular Malaysia in 1997, with 41 and 4 deaths, respectively (Chan et al., 2000). The largest outbreak so far, occurred in Taiwan in 1998 where an estimated 1.5 million people were infected with 405 children being hospitalised, of which 78 died (Wang et al., 2002). The recent epidemic in China in 2008, recorded 0.5 million cases with 126 deaths (Zhang et al., 2009, 2010). Many countries including Japan, Singapore, Sarawak, Vietnam and Peninsular Malaysia have ex-perienced cyclical epidemics that occur every 2-3 years (Fujimoto et al., 2002; Podin et al., 2006; Tu et al., 20077; Apandi et al., 2011).

Most of these outbreaks not only caused huge hospital admission but also resulted in fatality. One of the most...
important findings of these outbreaks was the emergence of different strains of HEV71.

Following the 1997 outbreak in Sarawak, the Malaysian Ministry of Health (MOH) made a ruling that all HFMD cases with or without neurological manifestations must be notified. Since then, a surveillance system for monitoring HFMD has been established.

MATERIALS AND METHODS

Clinical samples such as vesicle swabs, throat swabs, rectal swabs and stool from hospitalized HFMD patients were collected from 15 states in Malaysia. They were screened for enterovirus (EV) by RT-PCR (Perera et al., 2004). Positive samples were cultured in rhabdomyosarcoma (RD) cells and harvested once cytopathic effect was observed.

Viral RNA was extracted using the QIAamp® Viral RNA Mini Kit (Hilden, Germany). RT-PCR with specific HEV71 primers (Tu et al., 2007) was used for complete VP1 gene amplification. All isolates were sequenced using PCR primers as described by Tu et al. (2007) and internal primers VP1 Int F and VP1 Int R (Apandi et al., 2011). Sequencing was performed by using the Big Dye Cycle sequencing kit version 3.0 and an ABI377 automated DNA sequencer (Applied Biosystems, Forster City, USA). The SeqMan and Megalign software modules in the Lasergene Suite of programs (DNASTAR, Madison, WI, USA) were used to format the nucleotide sequences. All sequences were BLAST searched (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and a phylogenetic tree was constructed by using the neighbour-joining method from the MEGA4 software (www.megasoftware.net).

RESULTS

In 2010, Institute for Medical Research (IMR) Kuala Lumpur, Malaysia received specimens from 634 hospitalised HFMD cases and EV was detected from 440 (69%) cases by RT-PCR. Of these, 36 isolates comprised of CA16, HEV71, CA5 and ECHO4 were isolated.

In 2011, we received specimens from only 268 HFMD cases and 185 (69%) were found positive for EV and 36 isolates of CA16, HEV71, CA10 and ECHO9 were detected. There was an increase in number of cases in 2012, specimens from 583 hospitalised cases were analysed and EV was detected in 407 cases (70%). Eighty five isolates of CA16, HEV71 and CoxB3 were isolated.

Overall, a total of 37 HEV71 strains were isolated with 10 isolates in 2010, 5 in 2011 and 22 in 2012. Details of the isolates are shown in Table 1.

Based on the complete VP1 gene which consists of 891 nucleotides, the phylogenetic tree revealed that all HEV71 circulating in Malaysia from 2010 to 2012 in this study belonged to the HEV71 subgenogroup B5. The tree is shown in Figure 1.

DISCUSSION

Analyzing the VP1 gene is very important to determine the relationships between the genogroups (Ggs) and pathogenicity. Based on this, HEV71 has been classified into three genogroups (Ggs) namely GgA, GgB and GgC (Brown et al., 1999). GgA was the prototype strain of HEV71, isolated in California, USA in 1970 (Schmidt et al., 1974) and has never been reported since. Another two Ggs, GgB evolved over the years into 5 subgenogroups: GgB1, GgB2, GgB3, GgB4 and GgB5; while GgC evolved into subgenogroup GgC1, GgC2, GgC3, GgC4 and GgC5. The genetic variation within genogroups was about 12% or was lesser than the variation between genogroups which was about 16.5 to 19.7% (Brown et al., 1999).

In Malaysia, HFMD cases are detected throughout the year. However, outbreaks of HFMD occur periodically nearly every 1 years. Many researchers have reported different strains of HEV71 in different outbreaks. The huge HFMD outbreak in Sarawak in 1997 (Cardosa et al., 2003) was the starting point of molecular epidemiology study of HEV71 in Malaysia. Several outbreaks in 2000 (8 fatalities) followed by outbreak in 2003 (no fatality) and in 2005 (two fatalities) (Chua and Kasri, 2011), had contributed more HEV71 genomic diversity.

GgB3 isolated in 1997, during the Sarawak outbreak, was documented as the first HEV71 strain circulating and associated with severe encephalitis and fatalities in Malaysia (Cardosa et al., 2003). To date, this strain has never been found circulating in peninsular Malaysia; indicating that GgB3 only appeared in very short period of time and confined to Sarawak State only for Malaysia. However, it has been isolated and reported in Japan at the same time (Fujimoto et al., 2002).

Between 1998 and 1999, HEV71 was still isolated from a few HFMD cases although there were no outbreaks reported. GgC1 was found to be circulating sporadically in 1998 in Sarawak (Cardosa et al., 2003) together with GgC2 in peninsular Malaysia (AbuBakar et al., 1999) from typical HFMD cases. However, GgC2 found circulating during the large HEV71 outbreak in Taiwan in 1998, was associated with fatal encephalitis (Wang et al., 2002).

HEV71 activity appeared low in 1999, and an analysis of 43 HEV71 isolates from peninsular Malaysia from 1997-2000 (Herrero et al., 2003) showed that GgB4 was the only predominant strain circulating in that year. Later in 2000, during the large outbreak of HFMD in peninsular Malaysia and Sarawak, GgB4 together with GgC1 emerged as the dominant strains (Chua and Kasri, 2011; Cardosa et al., 2003; Herrero et al., 2003). These two Ggs were also found widespread in the outbreak in Singapore and Taiwan, and continued to circulate in Malaysia in 2001 (Apandi et al., 2011), replacing GgB3.

GgC1 was found circulating in 2001, 2003, 2006 and 2007, mostly in peninsular Malaysia. From 2001 to 2009, 70 isolates from peninsular Malaysia and Sabah of HEV71 were analysed (Apandi et al., 2011). GgC1 was lastly detected in 2007 and it has neither been documented as the cause of large outbreak nor asso-
Table 1. Summary of patients’ gender, age, sample type, clinical diagnosis and GenBank accession number.

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Accession No.</th>
<th>Sample type</th>
<th>Sex/age</th>
<th>Diagnosis</th>
<th>Isolation year</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV1004-Terengganu-11</td>
<td>KC894856</td>
<td>V/S</td>
<td>M/5</td>
<td>HFMD</td>
<td>2011</td>
</tr>
<tr>
<td>EV1056-Terengganu-11</td>
<td>KC894866</td>
<td>T/S</td>
<td>M/2</td>
<td>HFMD</td>
<td>2011</td>
</tr>
<tr>
<td>EV1268-Pahang-11</td>
<td>KC894867</td>
<td>V/S</td>
<td>F/0.8</td>
<td>HFMD</td>
<td>2011</td>
</tr>
<tr>
<td>EV0978-Sarawak-11</td>
<td>KC894868</td>
<td>R/S</td>
<td>F/1.5</td>
<td>HFMD</td>
<td>2011</td>
</tr>
<tr>
<td>EV0984-Sarawak-11</td>
<td>KC894869</td>
<td>V/S</td>
<td>M/1.3</td>
<td>HFMD</td>
<td>2011</td>
</tr>
<tr>
<td>EV0691-Terengganu-10</td>
<td>KC894872</td>
<td>V/S</td>
<td>M/1</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV0733-Pinang-10</td>
<td>KC894873</td>
<td>T/S</td>
<td>F/2</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV0744-Johor-10</td>
<td>KC894874</td>
<td>T/S</td>
<td>F/1</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV0994-Terengganu-10</td>
<td>KC894875</td>
<td>V/S</td>
<td>M/2</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV1233-Kedah-10</td>
<td>KC894876</td>
<td>V/S</td>
<td>F/4</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV1297-Melaka-10</td>
<td>KC894877</td>
<td>T/S</td>
<td>M/3</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV1299-Melaka-10</td>
<td>KC894878</td>
<td>T/S</td>
<td>M/8</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV1301-Melaka-10</td>
<td>KC894879</td>
<td>V/S</td>
<td>M/6</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV1312-Johor-10</td>
<td>KC894880</td>
<td>T/S</td>
<td>M/1</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV1389-KLumpur-10</td>
<td>KC894881</td>
<td>Stool</td>
<td>M/0.5</td>
<td>HFMD</td>
<td>2010</td>
</tr>
<tr>
<td>EV0615-Johor-12</td>
<td>KC894882</td>
<td>T/S</td>
<td>M/1.5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0616-Johor-12</td>
<td>KC894883</td>
<td>T/S</td>
<td>F/0.5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0655-Kedah-12</td>
<td>KC894884</td>
<td>V/S</td>
<td>M/4</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0659-Pahang-12</td>
<td>KC894885</td>
<td>V/S, T/S</td>
<td>M/5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0665-Kelantan-12</td>
<td>KC894886</td>
<td>T/S</td>
<td>F/4</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0673-Johor-12</td>
<td>KC894887</td>
<td>T/S</td>
<td>F/2.1</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0710-Johor-12</td>
<td>KC894888</td>
<td>R/S</td>
<td>M/1.7</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0769-Johor-12</td>
<td>KC894889</td>
<td>T/S</td>
<td>F/2</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0775-Johor-12</td>
<td>KC894890</td>
<td>T/S</td>
<td>F/1.7</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0779-Johor012</td>
<td>KC894891</td>
<td>V/S</td>
<td>F/7</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0791-Johor-12</td>
<td>KC894892</td>
<td>R/S</td>
<td>F/1</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0834-Johor-12</td>
<td>KC894893</td>
<td>T/S</td>
<td>M/2</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0891-Johor-12</td>
<td>KC894894</td>
<td>T/S</td>
<td>F/1.2</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0894-Kedah-12</td>
<td>KC894895</td>
<td>V/S</td>
<td>M/2.7</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0896-Johor-12</td>
<td>KC894896</td>
<td>T/S</td>
<td>F/2</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0953-Johor-12</td>
<td>KC894897</td>
<td>T/S</td>
<td>M/1.6</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0961-Johor-12</td>
<td>KC894898</td>
<td>T/S</td>
<td>F/1.2</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV1002-Johor-12</td>
<td>KC894899</td>
<td>R/S</td>
<td>M/5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV1003-Johor-12</td>
<td>KC894900</td>
<td>R/S</td>
<td>M/2.5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV1170-Selangor-12</td>
<td>KC894901</td>
<td>T/S</td>
<td>M/5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV1325-Johor-12</td>
<td>KC894902</td>
<td>T/S</td>
<td>F/1.5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
<tr>
<td>EV0997-Pahang-12</td>
<td>KC894903</td>
<td>T/S</td>
<td>M/1.5</td>
<td>HFMD</td>
<td>2012</td>
</tr>
</tbody>
</table>

T/S = throat swab; R/S = rectal swab; V/S = vesicle swab; M = male; F = female; age in years.

A new subgenogroup in GgC, named GgC4, first emerged in China in early 2000. It later became a predominant strain in Taiwan in 2004 (Lin et al., 2006) and was responsible for huge outbreaks of HFMD in Shandong and Fuyang, China in 2007-2008 (Zhang et al., 2009, 2010).

However in Malaysia, only one GgC4 was detected from HFMD cases in 2004 (Apandi et al., 2011) and other strains, GgC3 and GgC5, so far have never been reported (Apandi et al., 2011; AbuBakar et al., 1999; Herrero et al., 2003). The GgC3 was found only during the major HEV71 outbreak in Korea in 2000 and GgC5 circulated widely in Southern Vietnam in 2005 (Tu et al., 2007).

Over the years, HEV71 in GgB has evolved. GgB3 that emerged in 1997 was displaced by GgB4 in 2000 and 2001. In 2003, the GgB4 was displaced by GgB5 and since then, from 2004 to 2009, GgB5 became the only predominant strain in both peninsular Malaysia and Sarawak (Apandi et al., 2011). In this study, GgB5 was still found to be the dominant strain from 2010 to 2012.
Figure 1. Phylogenetic tree of HEV71 based on the complete VP1 gene. Genogroups and subgenogroups are indicated by square brackets with CA16-G10 as an outgroup. HEV71 isolates in 2010, 2011 and 2012 are indicated in blue, purple and red, respectively, together with representative retrieved from GenBank.
and was the cause of the 2010 HEV71 outbreak in Malaysia.

Hence, for the past 25 years, 6 strains of HEV71, 3 from GgB and 3 from GgC were circulating in Malaysia. In GgB, GgB3 was isolated in 1997 and was followed by GgB4 in 2000-2001 which was later replaced by GgB5 from 2003 till now. In GgC, GgC1 was first detected in 1997 in Sarawak, continued to circulate in peninsular in 2001, 2003, 2006 and 2007, while GgC2 circulated in 1998 and GgC4 in 2007.

**Conflict of Interests**

The author(s) have not declared any conflict of interests.

**ACKNOWLEDGEMENTS**

We thank the Director General of Health and the Director of the Institute for Medical Research for permission to publish this article. This research project was funded under the Virology Operational Budget 2012.

**REFERENCES**


